Matisse Pharmaceuticals BV was founded in 2014 as a startup with the main objective to develop a therapeutic product for the treatment of sepsis. The company acquired a worldwide exclusive license on the heparin technology. Matisse Pharmaceuticals is based at the Brightlands Chemelot Campus in Geleen, The Netherlands.
The implementation of the M6229 therapy will be an important step forward in the treatment of severe sepsis and septic shock. The company can rely on a flexible organization, a vast network and the infrastructure and facilities required to execute the clinical development program. The team is experienced in clinical development and manufacturing of medicinal products and has access to in-house facilities such as cleanrooms and laboratories.